Study of a New Protein Marker for Detecting Recurrence in Liver Cancer Patients Comparing Recurrent and Primary Liver Cancer Cases in Adults Aged 18 to 75

What this Trial Is About

Researchers are evaluating a specific protein to see if it can act as a new marker for detecting the return of liver cancer. The study focuses on patients with recurrent liver cancer and compares them to those with primary liver cancer. The main goal is to find out if higher levels of this protein are linked to liver cancer coming back and if it can be used to monitor recurrence early. The study divides participants into two groups a training set of 50 recurrent liver cancer patients with high protein levels and a validation set of 250 recurrent liver cancer patients to confirm findings. Participants will provide blood samples and undergo regular follow-up visits. Clinical data such as medical history and treatment outcomes will also be collected and carefully checked for quality and accuracy. Participants will be monitored through blood tests and follow-up visits every few months to collect data on their health and protein levels. Researchers will measure the proteins accuracy in detecting cancer return, along with survival rates and time until disease progression over up to 5 years. Personal information will be securely stored, and ethical standards are followed throughout the study.

Recurrent Liver Cancer: Reconceptualization and Reevaluation